In a recent issue of Breast Cancer Research, Watson and Gusterson wrote a viewpoint article [1] about our strategy for developing a prophylactic breast cancer vaccine [2] . Th e authors base much of their view on several misconceptions and misrepresentations that we wish to clarify.
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We did not immunize mice with an antibody as the authors claim in their abstract. We immunized mice with a single injection of whole recombinant mouse α-lactalbumin protein, and this single immunization provided highly signifi cant protection and therapy against the growth of tumors in several widely used mouse models for breast cancer.
Th e authors indicate that our 'approach was based on the hypothesis that removal of an organ will provide protection against cancer developing in that organ' [1] . Th e notion that excised organs have decreased risk for developing tumors is obviously simplistic and misrepresents our actual hypothesis stated in the fi rst sentence of our article: 'a full-strength autoimmune attack suffi cient to induce organ-specifi c failure may provide protection and therapy against tumors derived from the targeted organ' [2] .
Th e viewpoint questions the effi cacy of our strategy by claiming that 'milk proteins are expressed in the gland with every oestrus cycle' [1] but fails to indicate that αlactalbumin is not one of these milk proteins, because its expression in mice occurs only during late stages of gestation and reaches maximal expression only upon lactation [3] .
Th e authors cite two studies supporting their contention that α-lactalbumin is not expressed in human breast tumors but fail to cite 11 other studies showing that αlactalbumin is expressed in human breast tumors [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . Th is focus on target expression in mature tumors is moot since prophylactic vaccination requires eff ective targeting of proteins expressed in the emerging developing tumor perhaps as early as the initial dysplastic stages and not in the fully evolved primary and metastatic tumors.
In regard to the signifi cant inhibition of 4T1 breast tumor growth that we observed in α-lactalbuminvaccinated BALB/c mice, the authors state: 'If the experiments had been continued for longer than 32 days, it seems very likely that there would be no real diff erence between the immunised mice and mock-immunised mice in terms of tumour burden' [1] . We disagree with the authors' speculation about what would have occurred since inhibition in growth of primary 4T1 tumors is more often associated with decreased metastasis and overall increased survival [15] .
Perhaps the biggest misconception was the authors' belief that the target population for our vaccine will be teenage girls. We have never proposed this. Th e design of our vaccine was based on two complementary events that take place in women as they age, namely an increasing risk for developing breast cancer and a corresponding decreasing need for using the aging breast and its retired breast-specifi c proteins for lactation. Th us, our target population has always been women who are more than 40 years old and has never been teenagers as assumed by the authors. Th is is clearly stated in the last sentence of our abstract [2] .
Finally, we agree with the authors that women diff er considerably from mice and that there is legitimate concern that α-lactalbumin vaccination may target lactational foci in breasts of non-lactating women. However, the authors failed to indicate that, in the study they cited [16] , there was no quantifi cation of the frequency of such foci and that the appearance of these foci in the breasts of non-lactating women was signifi cantly associated with the use of contraceptive hormones available in the late 1970s. We believe that the concern regarding infl ammatory consequences in vaccinating women in their 40s is real but should be resolved in phase I safety trials and not in a selective interpretation of old, controversial, and sometimes confl icting literature focused on protein expression in mature tumors rather than in the targeted emerging tumor and on non-quantitative studies involving women taking contraceptive sex hormones.
We remain delighted that our prototypic embryonic vaccine and the implications of our overall strategy for developing a much-needed safe and eff ective prophylaxis against breast cancer by extending vaccine target selection to retired self-proteins have resonated globally and stirred the hopes of so many breast cancer patients around the world.
